Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Imcera

This article was originally published in The Gray Sheet

Executive Summary

Chemical, animal and human health products manufacturer expects to take a "significant restructuring charge" in the fourth quarter ending in June. The Northbrook, Illinois-based company plans "major, discrete actions to improve and sustain future earnings prospects and profitability, the greatest part of which...will relate to Pitman-Moore," the group's ailing animal health care unit, according to a March 9 press release. As a result of lackluster performance of its Pitman-Moore and Mallinckrodt Specialty Chemicals units, Imcera anticipates that earnings per share for the third quarter ending March 31 will be "several cents below" the 42 cents from continuing operations in the same period last year. For FY 1993, the firm expects earnings per share to be "only slightly above" the $1.65 reported in 1992, excluding the planned restructuring charge. In December, Imcera announced a management shift tied to Pitman-Moore's lagging performance ("The Gray Sheet" Dec. 14, p. 32).

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel